Cargando…

BTLA as a biomarker and mediator of sepsis-induced immunosuppression

Recent research indicates that T-lymphocyte dysfunction may contribute to sepsis-associated morbidity and mortality. B and T lymphocyte attenuator (BTLA) is a co-inhibitory receptor expressed by T lymphocytes and B lymphocytes that is important in regulating lymphocyte activation during inflammation...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sherwood, Edward R, Hotchkiss, Richard S
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2013
Materias:	Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4059397/ https://www.ncbi.nlm.nih.gov/pubmed/24321139 http://dx.doi.org/10.1186/cc13143

Ejemplares similares

BTLA/HVEM Axis Induces NK Cell Immunosuppression and Poor Outcome in Chronic Lymphocytic Leukemia
por: Sordo-Bahamonde, Christian, et al.
Publicado: (2021)

Immunotherapy - a potential new way forward in the treatment of sepsis
por: Payen, Didier, et al.
Publicado: (2013)

Immunoadjuvant therapy in sepsis: novel strategies for immunosuppressive sepsis coming down the pike
por: Watanabe, Eizo, et al.
Publicado: (2018)

BTLA inhibition has a dominant role in the cis-complex of BTLA and HVEM
por: Battin, Claire, et al.
Publicado: (2022)

Targeting of B and T lymphocyte associated (BTLA) prevents graft-versus-host disease without global immunosuppression
por: Albring, Jörn C., et al.
Publicado: (2010)

The role of natural killer cells in the pathogenesis of sepsis: the ongoing enigma
por: Bohannon, Julia, et al.
Publicado: (2012)

Biomarkers for late-onset neonatal sepsis
por: Polin, Richard A, et al.
Publicado: (2010)

Immune Checkpoints: Novel Therapeutic Targets to Attenuate Sepsis-Induced Immunosuppression
por: McBride, Margaret A., et al.
Publicado: (2021)

Roles of BTLA in Immunity and Immune Disorders
por: Ning, Zhaochen, et al.
Publicado: (2021)

Lymphocyte HVEM/BTLA co-expression after critical illness demonstrates severity indiscriminate upregulation, impacting critical illness-induced immunosuppression
por: Wakeley, Michelle E., et al.
Publicado: (2023)

LIGHT/BTLA polymorphisms and antibody-mediated-rejection after heart transplantation
por: Marrón-Liñares, Grecia M., et al.
Publicado: (2018)

Tumors recycle glucocorticoids to drive Treg-mediated immunosuppression
por: Swatler, Julian, et al.
Publicado: (2023)

Apolipoprotein M - a new biomarker in sepsis
por: Christoffersen, Christina, et al.
Publicado: (2012)

The International Sepsis Forum's controversies in sepsis: how will sepsis be treated in 2051?
por: Abraham, Edward
Publicado: (2002)

Sepsis-Induced Immunosuppression in Neonates
por: Hibbert, Julie E., et al.
Publicado: (2018)

A Test Identifying Biomarkers of Immunosuppression-Related Adverse Events in Kidney Transplant Recipients
por: Legendre, Christophe
Publicado: (2019)

Rapid diagnosis of sepsis using biomarker signatures
por: Silman, Nigel James
Publicado: (2013)

Shedding metabo‘light’ on the search for sepsis biomarkers
por: dos Santos, Claudia C.
Publicado: (2015)

PSP/reg: a new stone in sepsis biomarkers?
por: Busani, Stefano, et al.
Publicado: (2012)

Penkid: A Novel Biomarker of Reduced GFR in Sepsis
por: Moledina, Dennis G.
Publicado: (2018)

Disulfide-Linked Peptides for Blocking BTLA/HVEM Binding
por: Spodzieja, Marta, et al.
Publicado: (2020)

BTLA Expression and Function Are Impaired on SLE B Cells
por: Wiedemann, Annika, et al.
Publicado: (2021)

Biomarkers in SIRS and sepsis: Quo vadis?
por: Novotny, Alexander R.
Publicado: (2010)

Collagen-related biomarkers in severe sepsis: a big stretch?
por: Morrison, Gavin, et al.
Publicado: (2009)

A crucial role for HVEM and BTLA in preventing intestinal inflammation
por: Steinberg, Marcos W., et al.
Publicado: (2008)

Microparticles: markers and mediators of sepsis-induced microvascular dysfunction, immunosuppression, and AKI
por: Souza, Ana Carolina P., et al.
Publicado: (2015)

Intragenic Variations in BTLA Gene Influence mRNA Expression of BTLA Gene in Chronic Lymphocytic Leukemia Patients and Confer Susceptibility to Chronic Lymphocytic Leukemia
por: Karabon, Lidia, et al.
Publicado: (2016)

Matrix metalloproteinases and their inhibitors: promising novel biomarkers in severe sepsis?
por: Hoffmann, Ursula, et al.
Publicado: (2009)

Predicting outcome in patients with sepsis: new biomarkers for old expectations
por: Charles, Pierre-Emmanuel, et al.
Publicado: (2014)

Leptin in sepsis: a well-suited biomarker in critically ill patients?
por: Bracho-Riquelme, Rodolfo Leonel, et al.
Publicado: (2010)

Cancer immunotherapy by immunosuppression
por: Prehn, Richmond T, et al.
Publicado: (2010)

Finding new therapies for sepsis: the need for patient stratification and the use of genetic biomarkers
por: Hobson, Michael J, et al.
Publicado: (2011)

Modification of BTLA signaling motifs in TIL exhibits positive signals that mediate anti-tumor control
por: Ritthipichai, Krit, et al.
Publicado: (2015)

The first step in utilizing immune-modulating therapies: immune status determination
por: Caldwell, Charles C, et al.
Publicado: (2011)

Friend or Foe: Prognostic and Immunotherapy Roles of BTLA in Colorectal Cancer
por: Song, Jingjing, et al.
Publicado: (2020)

Investigation of BTLA tagging variants with risk of esophagogastric junction adenocarcinoma
por: Tang, Weifeng, et al.
Publicado: (2019)

Mechanisms of sepsis‐induced immunosuppression and immunological modification therapies for sepsis
por: Ono, Satoshi, et al.
Publicado: (2018)

Uncovering a novel function of BTLA on tumor-infiltrating CD8+ T cells
por: Haymaker, Cara, et al.
Publicado: (2013)

Cancer surgery induces inflammation, immunosuppression and neo-angiogenesis, but is it influenced by analgesics?
por: Forget, Patrice, et al.
Publicado: (2013)

BTLA dysregulation correlates with poor outcome and diminished T cell-mediated antitumor responses in chronic lymphocytic leukemia
por: Sordo-Bahamonde, Christian, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_1uoscr4v67je4dt5k5cpcgov3s